J. Fagerberg

发表

Introduction: The Heterogeneity of Innovation: Evidence from the Community Innovation Surveys

J. Fagerberg, D. Mowery, Paul Nightingale, 2012 .

Innovation: Exploring the knowledge base

J. Fagerberg, Morten Fosaas, Koson Sapprasert, 2012, posted content for vor conflict notifications.

Innovation studies—The emerging structure of a new scientific field

J. Fagerberg, B. Verspagen, 2009 .

Innovation: A Guide to the Literature

J. Fagerberg, 2003 .

The Oxford handbook of innovation

J. Fagerberg, D. Mowery, R. Nelson, 2006 .

Exploring the emerging knowledge base of ‘the knowledge society’

J. Fagerberg, B. Martin, H. Landström, 2012 .

National innovation systems, capabilities and economic development

J. Fagerberg, Martin Srholec, 2008 .

The Competitiveness of Nations: Why Some Countries Prosper While Others Fall Behind

J. Fagerberg, Martin Srholec, M. Knell, 2007 .

Innovation policy: What, why, and how

J. Fagerberg, J. Edler, 2017 .

Schumpeter and the revival of evolutionary economics: an appraisal of the literature

J. Fagerberg, 2003 .

Innovation Policy: Rationales, Lessons and Challenges

Jan Fagerberg, J. Fagerberg, 2017 .

Innovation Systems for Transformations towards Sustainability? Taking the Normative Dimension Seriously

Andreas Pyka, Matthias Mueller, Job Timmermans, 2017 .

National innovation systems : The emergence of a new approach

Jan Fagerberg, J. Fagerberg, Koson Sapprasert, 2011 .

The triple challenge for Europe: economic development, climate change, and governance

J. Fagerberg, B. Martin, S. Laestadius, 2015 .

Technology and regulation in a classical model of economic growth

J. Fagerberg, 1991 .

Technology and International Differences in Growth Rates

Jan Fagerberg, J. Fagerberg, 1994 .

Technology, Growth and Unemployment across European Regions

Marjolein C.J. Caniëls, Bart Verspagen, Jan Fagerberg, 1997 .

User-Producer Interaction, Learning and Comparative Advantage

Jan Fagerberg, J. Fagerberg, 1993 .

Mission (im)possible? Mobilizing innovation – and policies supporting it – in the transition to sustainability

J. Fagerberg, 2019 .

Mobilizing innovation for sustainability transitions: A comment on transformative innovation policy

J. Fagerberg, 2018, Research Policy.

Schumpeter and the revival of evolutionary economics: an appraisal of the literature

J. Fagerberg, 2003 .

Mobilizing for change: A study of research units in emerging scientific fields

Magnus Gulbrandsen, Tommy Høyvarde Clausen, Jan Fagerberg, 2012 .

Technology and competitiveness

Jan Fagerberg, J. Fagerberg, 1996 .

Global Value Chains, National Innovation Systems and Economic Development

J. Fagerberg, Martin Srholec, B. Lundvall, 2018, The European Journal of Development Research.

Knowledge, Capabilities, and the Poverty Trap: The Complex Interplay Between Technological, Social, and Geographical Factors

J. Fagerberg, Martin Srholec, 2013 .

Christopher Freeman: Social Science Entrepreneur

J. Fagerberg, M. Bell, B. Martin, 2011 .

Capabilities, Economic Development, Sustainability

Martin Srholec, Jan Fagerberg, J. Fagerberg, 2017 .

Coping with Societal Challenges: Lessons for Innovation Policy Governance

J. Fagerberg, G. Hutschenreiter, 2020, Journal of Industry, Competition and Trade.

Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).

J. Fagerberg, A. Osterborg, C. Lindemalm, 1991, Acta oncologica.

Effect of monoclonal antibody 17‐1A and gm‐CSF in patients with advanced colorectal carcinoma—long‐lasting, complete remissions can be induced

J. Fagerberg, C. Lindemalm, G. Masucci, 1993, International journal of cancer.

Different dose regimens of the mouse monoclonal-antibody 17-1a for therapy of patients with metastatic colorectal-carcinoma.

J. Fagerberg, K. Fox, K. Thor, 1995, International journal of oncology.

Esophageal cancer in Stockholm county 1978–1995

J. Fagerberg, D. Stockeld, L. Granström, 2007, Acta oncologica.

Serial Fine Needle Cytology in the Diagnosis of Esophageal Cancer

J. Fagerberg, D. Stockeld, L. Granström, 2002, Acta Cytologica.

Percutaneous endoscopic gastrostomy for nutrition in patients with oesophageal cancer.

J. Fagerberg, D. Stockeld, L. Granström, 2001, The European journal of surgery = Acta chirurgica.

A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus

H. Strander, J. Fagerberg, G. Gustafsson, 2001, Acta oncologica.

Targeting human Ep‐CAM in transgenic mice by anti‐idiotype and antigen based vaccines

J. Fagerberg, H. Mellstedt, F. Campbell, 2004, International journal of cancer.

Innovation, technology and the global knowledge economy: Challenges for future growth

J. Fagerberg, 2006 .

Combined treatment modalities in esophageal cancer. Should chemotherapy be included?

J. Fagerberg, R. Lewensohn, D. Stockeld, 1994, Acta oncologica.

Structural change and economic policy: the Norwegian model under pressure

J. Fagerberg, Å. Cappelen, L. Mjøset, 1992 .

myeloma regions of the tumor derived immunoglobulin heavy chain in multiple T-cell epitopes within the complementarity-determining and framework

J. Fagerberg, A. Österborg, H. Mellstedt, 2013 .

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma.

J. Fagerberg, A. Osterborg, H. Mellstedt, 2003, Blood.

Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA

J. Fagerberg, H. Mellstedt, G. Ullenhag, 2004, Cancer Immunology, Immunotherapy.

Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)

J. Fagerberg, H. Wigzell, M. Steinitz, 1994, Cancer Immunology, Immunotherapy.

The Role of Innovation Policy in Simultaneously Addressing Economic, Environmental and Governance Challenges

J. Fagerberg, B. Martin, S. Laestadius, 2017 .

Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.

J. Fagerberg, J. Shetye, A. Osterborg, 1999, Current opinion in hematology.

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

J. Fagerberg, H. Mellstedt, B. Wahrén, 1998, Cancer Immunology, Immunotherapy.

One Europe or several? Causes and consequences of the European stagnation

J. Fagerberg, B. Verspagen, 2014 .

Innovation and Competitiveness

J. Fagerberg, 2004 .

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Jan Fagerberg, René Bruno, Pascal Girard, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent.

J. Fagerberg, E. Van Cutsem, J. O’Shaughnessy, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capabilities, Competitiveness, Nations

J. Fagerberg, Martin Srholec, 2015 .

Immunogenic regions of the GA733–2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma

J. Fagerberg, U. Harmenberg, H. Mellstedt, 2002, Cancer Immunology, Immunotherapy.

Ga733/EpCAM as a Target for Passive and Active Specific Immunotherapy in Patients with Colorectal Carcinoma

J. Fagerberg, H. Mellstedt, P. Ragnhammar, 2000, Annals of the New York Academy of Sciences.

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma

J. Fagerberg, J. Shetye, B. Nilsson, 1999, Cancer Immunology, Immunotherapy.

The therapeutic use of monoclonal antibodies in colorectal carcinoma.

J. Fagerberg, J. Shetye, A. Osterborg, 1991, Seminars in oncology.

Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.

J. Fagerberg, A. Lefvert, M. Jeddi-Tehrani, 1998, Blood.

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

J. Fagerberg, R. Advani, M. Beylot-Barry, 2009 .

Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma

J. Fagerberg, J. Wersäll, C. Lindemalm, 1993, Medical oncology and tumor pharmacotherapy.

Immunization Effect of Monoclonal Antibodies against Tumor‐Associated Antigens during Cancer Treatment

J. Fagerberg, H. Mellstedt, H. Wigzell, 1993, Annals of the New York Academy of Sciences.

Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy.

J. Fagerberg, 1996, Medical oncology.

Innovation , growth and economic development : Why some countries succeed and others don ’ t By

J. Fagerberg, B. Verspagen, 2003 .

Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.

J. Fagerberg, H. Wigzell, H. Mellstedt, 1999, Cellular immunology.

T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody

J. Fagerberg, H. Mellstedt, M. Jeddi-Tehrani, 2005, Cancer Immunology, Immunotherapy.

Induction of a T‐ and B‐cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb‐treated patient

J. Fagerberg, H. Mellstedt, P. Wersäll, 1997, International journal of cancer.

What Do We Know About Innovation and Socio-economic Change? Lessons from the TEARI Project

J. Fagerberg, 2006 .

Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.

J. Fagerberg, H. Wigzell, M. Steinitz, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Global dynamics, capabilities and the crisis

J. Fagerberg, Martin Srholec, 2016, Journal of Evolutionary Economics.

Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17–1A develop a cellular response (DTH) to the “internal image of the antigen” (ab2)

J. Fagerberg, P. Biberfeld, M. Steinitz, 1991, International journal of cancer.

Coping with Societal Challenges: Lessons for Innovation Policy Governance

J. Fagerberg, G. Hutschenreiter, 2020, Journal of Industry, Competition and Trade.

The Three Great Issues Confronting Europe – Economic, Environmental and Political

J. Fagerberg, B. Martin, S. Laestadius, 2018, Innovation Systems, Policy and Management.

Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)

J. Fagerberg, H. Wigzell, H. Mellstedt, 1993, Cancer Immunology, Immunotherapy.

Chemotherapy and immunotherapy of colorectal cancer

J. Fagerberg, H. Mellstedt, A. Österborg, 1991, Medical oncology and tumor pharmacotherapy.

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies

J. Fagerberg, L. Hansson, H. Mellstedt, 1995, Cancer Immunology, Immunotherapy.

Idiotypic network responses and anti-idiotypes in cancer therapy.

J. Fagerberg, H. Mellstedt, 1997 .

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A

J. Fagerberg, H. Mellstedt, P. Ragnhammar, 1996, Cancer Immunology, Immunotherapy.

Technological dynamics and social capability: US states and European nations

M. Feldman, J. Fagerberg, Martin Srholec, 2014 .

Do Global Production Networks and Digital Information Systems make Knowledge spatially fluid

Dieter Ernst, Jarle Hildrum, Jan Fagerberg, 2002 .

Innovation, Catching-Up and Growth

J. Fagerberg, 1989 .

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

Production of neutralizing granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) antibodies in carcinoma patients following GM‐CSF combination therapy

J. Fagerberg, M. Wadhwa, C. Bird, 1996, Clinical and experimental immunology.

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma

Jan Fagerberg, J. Fagerberg, U. Harmenberg, 1999, Cancer Immunology, Immunotherapy.

T‐cell‐epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma

J. Fagerberg, U. Harmenberg, H. Mellstedt, 1999, International journal of cancer.

Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors.

J. Fagerberg, D. Petrylak, O. O’Connor, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.

J. Fagerberg, H. Wigzell, H. Mellstedt, 1995, Cancer research.

Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man.

J. Fagerberg, A. Osterborg, H. Mellstedt, 1999, European journal of cancer.

Vaccination with Ep-CAM Protein or Anti-Idiotypic Antibody Induces Th1-Biased Response against MHC Class I- and II-Restricted Ep-CAM Epitopes in Colorectal Carcinoma Patients

J. Fagerberg, H. Mellstedt, M. Steinitz, 2004, Clinical Cancer Research.

RECOMBINANT CARCINOEMBRYONIC ANTIGEN AND GRANULOCY-TE-MACROPHAGE COLONY-STIMULATING FACTOR FOR ACTIVE IMMUNIZATION OF COLORECTAL CARCINOMA PATIENTS

J. Fagerberg, H. Mellstedt, B. Wahrén, 1995 .

Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II study.

J. Fagerberg, J. Shetye, H. Mellstedt, 1995, Cancer biotherapy.

Technological progress, structural change and productivity growth: a comparative study

Jan Fagerberg, J. Fagerberg, 2000 .

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

J. Fagerberg, P. Kufer, T. Raum, 2010, Cancer Cell International.

MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.

Jan Fagerberg, J. Fagerberg, H. Mellstedt, 2002, Hybridoma and hybridomics.

Response to chemoradiatiotherapy in squamous cell carcinoma of the esophagus: evaluation of some prognostic factors

J. Fagerberg, S. Falkmer, U. Falkmer, 2009 .

Innovation and Economic Development

Jan Fagerberg, Martin Srholec, Bart Verspagen, 2009 .

Innovation and Catching-Up

Jan Fagerberg, J. Fagerberg, M. Godinho, 2006 .

Regional Disparities in Income and Unemployment in Europe

J. Fagerberg, B. Verspagen, F. Castellacci, 2003 .

Innovation–diffusion, the economy and contemporary challenges: a comment

J. Fagerberg, B. Verspagen, 2020 .

Technology-gaps, innovation-diffusion and transformation:an evolutionary interpretation

Bart Verspagen, Jan Fagerberg, J. Fagerberg, 2002 .

Technology and competitiveness

J. Fagerberg, 1996 .

The method of constant market shares analysis reconsidered

J. Fagerberg, Gunnar Sollie, 1987 .

Innovation - a New Guide

Jan Fagerberg, J. Fagerberg, 2013 .

A Layman's Guide to Evolutionary Economics

Jan Fagerberg, J. Fagerberg, 2002 .

A Layman ’ s Guide to Evolutionary Economics by Jan Fagerberg

J. Fagerberg, 2002 .

Technological revolutions, structural change & catching-up

J. Fagerberg, B. Verspagen, 2020 .

Innovation, Path Dependency, and Policy

David C. Mowery, Bart Verspagen, Jan Fagerberg, 2009 .

The Complex Interaction Between Global Production Networks, Digital Information Systems and International Knowledge Transfers

Dieter Ernst, Jarle Hildrum, Jan Fagerberg, 2010 .

The Role of Innovation in Development

Bart Verspagen, Martin Srholec, Jan Fagerberg, 2010 .

Technology and development: Unpacking the relationship(s)

J. Fagerberg, Martin Srholec, 2008 .

Catching up: What are the Critical Factors for success?

Jan Fagerberg, Martin Srholec, J. Fagerberg, 2005 .

The Triple Challenge for Europe: The Economy, Climate Change, and Governance

J. Fagerberg, B. Martin, S. Laestadius, 2016 .

Domestic Demand, Learning and Comparative Advantage

J. Fagerberg, 1994 .

A technology gap approach to why growth rates differ

Jan Fagerberg, J. Fagerberg, 1987 .

The evolution of Norway’s national innovation system

David C. Mowery, Bart Verspagen, Jan Fagerberg, 2009 .

Innovation, Path Dependency, and Policy: The Norwegian Case

David C. Mowery, Bart Verspagen, Jan Fagerberg, 2009 .

The economic challenge for Europe : adapting to innovation based growth

Jan Fagerberg, J. Fagerberg, 1999 .

Innovation studies: towards a new agenda

J. Fagerberg, E. Andersen, B. Martin, 2013 .

Competitiveness, Scale and R&D

Jan Fagerberg, J. Fagerberg, 1996 .

Is there a large-country advantage in high-tech?

J. Fagerberg, 1995 .

Interferon‐α/β can impede development of carcinogen‐induced squamous‐cell tumors in the esophagus of C57B1 mice

H. Strander, J. Fagerberg, C. Rubio, 1995 .

Working paper nr 12: The Impact of regional support on growth and convergence in the European Union

Fulvio Castellacci, Bart Verspagen, Jan Fagerberg, 2003 .

The Impact of EU Regional Support on Growth and Convergence in the European Union

J. Fagerberg, B. Verspagen, F. Castellacci, 2003 .

Heading for Divergence? Regional Growth in Europe Reconsidered*

J. Fagerberg, B. Verspagen, 1996 .

Innovation studies : evolution and future challenges

Ben R. Martin, Esben Sloth Andersen, Jan Fagerberg, 2013 .

European economic integration : Nordic perspective

J. Fagerberg, Lars Lundberg, 1993 .

Innovation Systems and Policy: A Tale of Three Countries

J. Fagerberg, 2016 .

Capabilities, diversification & economic dynamics in European Regions

J. Fagerberg, Martin Srholec, 2022, The Journal of Technology Transfer.

The State University of Applied Sciences in Plock INNOVATIONS IN THE POLISH ICT SECTOR IN THE YEARS 2014 – 2016

J. Fagerberg, D. Mowery, R. Nelson, 2019 .

East Asian Growth: A Critical Assessment

J. Fagerberg, A. Cappelen, 1995 .

Productivity, R&D Spillovers and Trade

J. Fagerberg, B. Verspagen, 1998 .

Explaining regional economic performance : The role of competitiveness, specialization and capabilities

J. Fagerberg, Martin Srholec, 2017 .

Technological Dynamics and Social Capability: Comparing U.S. States and European Nations

M. Feldman, J. Fagerberg, Martin Srholec, 2012 .

The changing global economic landscape: What are the factors that matter?

J. Fagerberg, 2010 .

'Modern Capitalism' in the 1970s and 1980s

J. Fagerberg, B. Verspagen, 1999 .

Europe, a long view

J. Fagerberg, B. Verspagen, P. Guerrieri, 1999 .

' Modern Capitalism ' in the 1970 s and 1980 s by

J. Fagerberg, B. Verspagen, 2022 .

EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.

J. Fagerberg, P. Wen, A. Idbaih, 2022, Journal of Clinical Oncology.

THE ROLE OF “ CAPABILITIES ” IN DEVELOPMENT : HOW SOME COUNTRIES MANAGE TO CATCH UP

J. Fagerberg, Martin Srholec, 2006 .

The Triple Challenge for Europe: The Economy, Climate Change and Governance

J. Fagerberg, B. Martin, S. Laestadius, 2016 .

The method of constant market shares analysis revisited

J. Fagerberg, Gunnar Sollie, 1985 .

Global dynamics, capabilities and the crisis

J. Fagerberg, Martin Srholec, 2016 .

The competitiveness of nations

J. Fagerberg, Martin Srholec, M. Knell, 2004 .

Innovation policy, national innovation systems and economic performance: In search of a useful theoretical framework

J. Fagerberg, 2015 .

Technology, Policy, Growth - Theory, Evidence and Interpretation

J. Fagerberg, 1996 .

The Impact of Regional Support on Growth and Convergence in the

J. Fagerberg, B. Verspagen, F. Castellacci, 2001 .

The Dynamics of Technology, Growth and Trade: A Schumpeterian Perspective

J. Fagerberg, 2007 .

Structural Changes in International Trade. Cause, Impact and Response

J. Fagerberg, Martin Srholec, 2004 .

The Competitiveness of Nations: Economic Growth in the ECE Region

J. Fagerberg, Martin Srholec, M. Knell, 2004 .

Bloom's Taxonomy for Standardizing BPM Education of IT Under-Graduates Students

Muhammad Anwar-ur-Rehman Pasha, Shaheen Pasha, J. Fagerberg, 2013 .

The evolution of Norway's national innovation system

J. Fagerberg, D. Mowery, B. Verspagen, 2009 .

Pharmacokinetics of cisplatin and its monohydrated complex in humans.

J. Fagerberg, R. Lewensohn, H. Ehrsson, 1996, Journal of pharmaceutical sciences.

Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

J. Fagerberg, H. Mellstedt, B. Nilsson, 2005, International journal of oncology.

Innovation-systems, path-dependency and policy: The co-evolution of science, technology and innovation policy and industrial structure in a small, resource-based economy

J. Fagerberg, D. Mowery, B. Verspagen, 2008 .

Innovation policy: What, why, and how

J. Fagerberg, J. Edler, 2017 .

Innovation Systems, Technology and Development: Unpacking the Relationships

J. Fagerberg, Martin Srholec, 2009 .

Handbook of the economics of innovation.

Bart Verspagen, Martin Srholec, Jan Fagerberg, 2010 .

Innovation and Innovation Policy in the Nordic Region

J. Fagerberg, Morten Fosaas, 2014 .

I Traditional Wisdom Questioned

J. Fagerberg, 2014 .

Europe at the Crossroads: The Challenge from Innovation-based Growth

Jan Fagerberg, J. Fagerberg, 2000 .

Ear tumours induced by experimental carcinogenesis in the rat: excision prevents early death

J. Fagerberg, C. Rubio, J. Shetye, 1994, International Journal of Colorectal Disease.

Catching up: What are the Critical Factors for success?

J. Fagerberg, Martin Srholec, 2005 .

Economic growth and technological change : an evolutionary interpretation

J. Fagerberg, B. Verspagen, Jan Fagerberg, 2010 .

DYNAMICS OF INDUSTRY AND INNOVATION: ORGANIZATIONS, NETWORKS AND SYSTEMS

J. Fagerberg, Martin Srholec, M. Knell, 2005 .

Innovation, growth and economic development: have the conditions for catch-up changed?

Bart Verspagen, Jan Fagerberg, J. Fagerberg, 2007 .

Convergence or divergence? The impact of technology on “why growth rates differ”

J. Fagerberg, 1995 .

East Asian Growth and the Japanese Model: A Critical Assessment of Recent Analyses

J. Fagerberg, 1995 .

Papers in Innovation Studies

J. Fagerberg, Martin Srholec, 2015 .

TRANSFORMATION: AN EVOLUTIONARY INTERPRETATION

J. Fagerberg, 2002 .

Lack of regional convergence

J. Fagerberg, B. Verspagen, A. Cappelen, 1999 .

Convergence or Divergence - The Impact of Technology

J. Fagerberg, 1995 .

Innovation studies - an emerging discipline (or what)? A study of the global network of innovation scholars

J. Fagerberg, B. Verspagen, 2006 .

International Competitiveness: Errata

J. Fagerberg, 1988 .

WORKING PAPER SERIES

J. Fagerberg, D. Ernst, J. Hildrum, 2010 .